Advertisement

Cellular and Molecular Neurobiology

, Volume 34, Issue 8, pp 1209–1221 | Cite as

Hesperidin Alleviates Cognitive Impairment, Mitochondrial Dysfunction and Oxidative Stress in a Mouse Model of Alzheimer’s Disease

  • Dongmei WangEmail author
  • Ling Liu
  • Xiaoying Zhu
  • Wenlan Wu
  • Yong Wang
Original Research

Abstract

The role of mitochondrial dysfunction and oxidative stress has been well-documented in Alzheimer’s disease (AD). Bioflavonoids are being utilised as neuroprotectants in the treatment of various neurological disorders, including AD. Therefore, we conducted this current study in order to explore the effects of hesperidin (a flavanone glycoside) against amyloid-β (Aβ)-induced cognitive dysfunction, oxidative damage and mitochondrial dysfunction in mice. Three-month-old APPswe/PS1dE9 transgenic mice were randomly assigned to a vehicle group, two hesperidin (either 50 or 100 mg/kg per day) groups, or an Aricept (2.5 mg/kg per day) group. After 16 weeks of treatment, although there was no obvious change in Aβ deposition in the hesperidin-treated (100 mg/kg per day) group, however, we found that the administration of hesperidin (100 mg/kg per day) resulted in the reduction of learning and memory deficits, improved locomotor activity, and the increase of anti-oxidative defense and mitochondrial complex I–IV enzymes activities. Furthermore, Glycogen synthase kinase-3β (GSK-3β) phosphorylation significantly increased in the hesperidin-treated (100 mg/kg per day) group. Taken together, these findings suggest that a reduction in mitochondrial dysfunction through the inhibition of GSK-3β activity, coupled with an increase in anti-oxidative defense, may be one of the mechanisms by which hesperidin improves cognitive function in the APPswe/PS1dE9 transgenic mouse model of AD.

Keywords

Hesperidin APPswe/PS1dE9 mice Cognitive ability Oxidative stress 

Abbreviations

AD

Alzheimer’s disease

Amyloid-β

ATP

Adenosine triphosphate

BSA

Bovine serum albumin

EGTA

Ethylene glycol tetraacetic acid

GSH

Glutathione

GSK-3β

Glycogen synthase kinase-3β

MTT

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-H-tetrazolium bromide

MDA

Malondialdehyde

ROS

Reactive oxygen species

SDH

Succinate dehydrogenase

SOD

Super oxide dismutase

TBARS

Thiobarbituric acid reactive substances

T-AOC

Total antioxidant capability

Notes

Acknowledgments

The present work was supported by National Natural Science Foundation of China (U1304806) and the Scientific Research Fund of Henan University of Science and Technology (NO. 09001664).

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. Agati G, Azzarello E, Pollastri S, Tattini M (2012) Flavonoids as antioxidants in plants: location and functional significance. Plant Sci 196:67–76PubMedCrossRefGoogle Scholar
  2. Arafa HM, Aly HA, Abd-Ellah MF, El-Refaey HM (2009) Hesperidin attenuates benzo[alpha] pyrene-induced testicular toxicity in rats via regulation of oxidant/antioxidant balance. Toxicol Ind Health 25:417–427PubMedCrossRefGoogle Scholar
  3. Auld DS, Kornecook TJ, Bastianetto S, Quirion R (2002) Alzheimer’s disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 68:209–245PubMedCrossRefGoogle Scholar
  4. Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neurosci 8:663–672PubMedCrossRefGoogle Scholar
  5. Berman SB, Hastings TG (1999) Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson’s disease. J Neurochem 73:1127–1137PubMedCrossRefGoogle Scholar
  6. Bevins RA, Besheer J (2006) Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study ‘recognition memory’. Nat Protoc 1:1306–1311PubMedCrossRefGoogle Scholar
  7. Blass JP (2003) Cerebrometabolic abnormalities in Alzheimer’s disease. Neurol Res 25:556–566PubMedCrossRefGoogle Scholar
  8. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254PubMedCrossRefGoogle Scholar
  9. Burbaeva G, Boksha IS, Savushkina OK, Turishcheva MS, Tereshkina EB, Starodubtseva LI et al (2012) Platelet cytochrome c-oxidase and glutamine synthetase-like protein in patients with mild cognitive impairment. Zh Nevrol Psikhiatr Im S S Korsakova 112:55–58PubMedGoogle Scholar
  10. Bussiere T, Bard F, Barbour R, Grajeda H, Guido T, Khan K et al (2004) Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. Am J Pathol 165:987–995PubMedCrossRefPubMedCentralGoogle Scholar
  11. Cha MY, Han SH, Son SM, Hong HS, Choi YJ, Byun J et al (2012) Mitochondria-specific accumulation of amyloid beta induces mitochondrial dysfunction leading to apoptotic cell death. PLoS ONE 7:e34929PubMedCrossRefPubMedCentralGoogle Scholar
  12. Choi EJ (2008) Antioxidative effects of hesperetin against 7,12-dimethylbenz(a)anthracene-induced oxidative stress in mice. Life Sci 82:1059–1064PubMedCrossRefGoogle Scholar
  13. Choi EJ, Ahn WS (2008) Neuroprotective effects of chronic hesperetin administration in mice. Arch Pharm Res 31:1457–1462PubMedCrossRefGoogle Scholar
  14. DaRocha-Souto B, Coma M, Perez-Nievas BG, Scotton TC, Siao M, Sanchez-Ferrer P et al (2012) Activation of glycogen synthase kinase-3 beta mediates beta-amyloid induced neuritic damage in Alzheimer’s disease. Neurobiol Dis 45:425–437PubMedCrossRefPubMedCentralGoogle Scholar
  15. Du H, Guo L, Yan S, Sosunov AA, McKhann GM, Yan SS (2010) Early deficits in synaptic mitochondria in an Alzheimer’s disease mouse model. Proc Natl Acad Sci U S A 107:18670–18675PubMedCrossRefPubMedCentralGoogle Scholar
  16. Eckert A, Hauptmann S, Scherping I, Rhein V, Muller-Spahn F, Gotz J et al (2008) Soluble beta-amyloid leads to mitochondrial defects in amyloid precursor protein and tau transgenic mice. Neurodegener Dis 5:157–159PubMedCrossRefGoogle Scholar
  17. Eckert GP, Renner K, Eckert SH, Eckmann J, Hagl S, Abdel-Kader RM et al (2012) Mitochondrial dysfunction—a pharmacological target in Alzheimer’s disease. Mol Neurobiol 46:136–150PubMedCrossRefGoogle Scholar
  18. Federico A, Cardaioli E, Da Pozzo P, Formichi P, Gallus GN, Radi E (2012) Mitochondria, oxidative stress and neurodegeneration. J Neurol Sci 322:254–262PubMedCrossRefGoogle Scholar
  19. Feldhaus P, Fraga DB, Ghedim FV, De Luca RD, Bruna TD, Heluany M et al (2011) Evaluation of respiratory chain activity in lymphocytes of patients with Alzheimer disease. Metab Brain Dis 26:229–236PubMedCrossRefGoogle Scholar
  20. Ferreiro E, Oliveira CR, Pereira CM (2008) The release of calcium from the endoplasmic reticulum induced by amyloid-beta and prion peptides activates the mitochondrial apoptotic pathway. Neurobiol Dis 30:331–342PubMedCrossRefGoogle Scholar
  21. Galati EM, Monforte MT, Kirjavainen S, Forestieri AM, Trovato A, Tripodo MM (1994) Biological effects of hesperidin, a citrus flavonoid. (Note I): antiinflammatory and analgesic activity. Farmaco 40:709–712PubMedGoogle Scholar
  22. Gaur V, Kumar A (2010) Hesperidin pre-treatment attenuates NO-mediated cerebral ischemic reperfusion injury and memory dysfunction. Pharmacol Rep 62:635–648PubMedCrossRefGoogle Scholar
  23. Gaur V, Aggarwal A, Kumar A (2011) Possible nitric oxide mechanism in the protective effect of hesperidin against ischemic reperfusion cerebral injury in rats. Indian J Exp Biol 49:609–618PubMedGoogle Scholar
  24. Gillardon F, Rist W, Kussmaul L, Vogel J, Berg M, Danzer K et al (2007) Proteomic and functional alterations in brain mitochondria from Tg2576 mice occur before amyloid plaque deposition. Proteomics 7:605–616PubMedCrossRefGoogle Scholar
  25. Golde TE (2007) The pathogenesis of Alzheimer’s disease and the role of Abeta42. CNS Spectr 12:4–6PubMedGoogle Scholar
  26. Handattu SP, Garber DW, Monroe CE, van Groen T, Kadish I, Nayyar G et al (2009) Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer’s disease. Neurobiol Dis 34:525–534PubMedCrossRefGoogle Scholar
  27. Hauptmann S, Keil U, Scherping I, Bonert A, Eckert A, Muller WE (2006) Mitochondrial dysfunction in sporadic and genetic Alzheimer’s disease. Exp Gerontol 41:668–673PubMedCrossRefGoogle Scholar
  28. Hauptmann S, Scherping I, Drose S, Brandt U, Schulz KL, Jendrach M et al (2009) Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging 30:1574–1586PubMedCrossRefGoogle Scholar
  29. Hitzeman N (2006) Cholinesterase inhibitors for Alzheimer’s disease. Am Fam Physician 74:747–749PubMedGoogle Scholar
  30. Huang SM, Tsai SY, Lin JA, Wu CH, Yen GC (2012) Cytoprotective effects of hesperetin and hesperidin against amyloid beta-induced impairment of glucose transport through downregulation of neuronal autophagy. Mol Nutr Food Res 56:601–609PubMedCrossRefGoogle Scholar
  31. Iijima K, Liu HP, Chiang AS, Hearn SA, Konsolaki M, Zhong Y (2004) Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: a potential model for Alzheimer’s disease. Proc Natl Acad Sci U S A 101:6623–6628PubMedCrossRefPubMedCentralGoogle Scholar
  32. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW et al (2004) Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113:1535–1549PubMedCrossRefPubMedCentralGoogle Scholar
  33. Kalpana KB, Devipriya N, Srinivasan M, Vishwanathan P, Thayalan K, Menon VP VP (2011) Evaluating the radioprotective effect of hesperidin in the liver of Swiss albino mice. Eur J Pharmacol 658:206–212PubMedCrossRefGoogle Scholar
  34. Kumar P, Kumar A (2010) Protective effect of hesperidin and naringin against 3-nitropropionic acid induced Huntington’s like symptoms in rats: possible role of nitric oxide. Behav Brain Res 206:38–46PubMedCrossRefGoogle Scholar
  35. Kung MP, Hou C, Zhuang ZP, Zhang B, Skovronsky D, Trojanowski JQ et al (2002) IMPY: an improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques. Brain Res 956:202–210PubMedCrossRefGoogle Scholar
  36. Laczo J, Vlcek K, Vyhnalek M, Vajnerova O, Ort M, Holmerova I et al (2009) Spatial navigation testing discriminates two types of amnestic mild cognitive impairment. Behav Brain Res 202:252–259PubMedCrossRefGoogle Scholar
  37. Liang KC, Hon W, Tyan YM, Liao WL (1994) Involvement of hippocampal NMDA and AMPA receptors in acquisition, formation and retrieval of spatial memory in the Morris water maze. Chin J Physiol 37:201–212PubMedGoogle Scholar
  38. Liu Y, Peterson DA, Kimura H, Schubert D (1997) Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J Neurochem 69:581–593PubMedCrossRefGoogle Scholar
  39. Manczak M, Park BS, Jung Y, Reddy PH (2004) Differential expression of oxidative phosphorylation genes in patients with Alzheimer’s disease: implications for early mitochondrial dysfunction and oxidative damage. Neuromolecular Med 5:147–162PubMedCrossRefGoogle Scholar
  40. Maurer I, Zierz S, Moller HJ (2000) A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol Aging 21:455–462PubMedCrossRefGoogle Scholar
  41. Mc Donald JM, Savva GM, Brayne C, Welzel AT, Forster G, Shankar GM et al (2010) The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 133:1328–1341PubMedCrossRefPubMedCentralGoogle Scholar
  42. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C et al (2005) Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47:191–199PubMedCrossRefPubMedCentralGoogle Scholar
  43. McLoughlin DM, Miller CC (1996) The intracellular cytoplasmic domain of the Alzheimer’s disease amyloid precursor protein interacts with phosphotyrosine-binding domain proteins in the yeast two-hybrid system. FEBS Lett 397:197–200PubMedCrossRefGoogle Scholar
  44. Menze ET, Tadros MG, Abdel-Tawab AM, Khalifa AE (2012) Potential neuroprotective effects of hesperidin on 3-nitropropionic acid-induced neurotoxicity in rats. Neurotoxicology 33:1265–1275PubMedCrossRefGoogle Scholar
  45. Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358PubMedCrossRefGoogle Scholar
  46. Paris D, Ganey NJ, Laporte V, Patel NS, Beaulieu-Abdelahad D, Bachmeier C et al (2010) Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer’s disease. J Neuroinflammation 7:17PubMedCrossRefPubMedCentralGoogle Scholar
  47. Parker WD Jr, Parks J, Filley CM, Kleinschmidt-DeMasters BK (1994) Electron transport chain defects in Alzheimer’s disease brain. Neurology 44:1090–1096PubMedCrossRefGoogle Scholar
  48. Petit-Paitel A, Brau F, Cazareth J, Chabry J (2009) Involvment of cytosolic and mitochondrial GSK-3beta in mitochondrial dysfunction and neuronal cell death of MPTP/MPP-treated neurons. PLoS ONE 4:e5491PubMedCrossRefPubMedCentralGoogle Scholar
  49. Picone P, Carrotta R, Montana G, Nobile MR, San Biagio PL, Di Carlo M (2009) Abeta oligomers and fibrillar aggregates induce different apoptotic pathways in LAN5 neuroblastoma cell cultures. Biophys J 96:4200–4211PubMedCrossRefPubMedCentralGoogle Scholar
  50. Ramful D, Bahorun T, Bourdon E, Tarnus E, Aruoma OI (2010) Bioactive phenolics and antioxidant propensity of flavedo extracts of Mauritian citrus fruits: potential prophylactic ingredients for functional foods application. Toxicology 278:75–87PubMedCrossRefGoogle Scholar
  51. Raza SS, Khan MM, Ahmad A, Ashafaq M, Khuwaja G, Tabassum R et al (2011) Hesperidin ameliorates functional and histological outcome and reduces neuroinflammation in experimental stroke. Brain Res 1420:93–105PubMedCrossRefGoogle Scholar
  52. Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22:659–661PubMedCrossRefGoogle Scholar
  53. Reddy PH, Beal MF (2008) Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer’s disease. Trends Mol Med 14:45–53PubMedCrossRefPubMedCentralGoogle Scholar
  54. Reddy PH, Tripathi R, Troung Q, Tirumala K, Reddy TP, Anekonda V et al (2012) Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer’s disease: implications to mitochondria-targeted antioxidant therapeutics. Biochim Biophys Acta 1822:639–649PubMedCrossRefPubMedCentralGoogle Scholar
  55. Ryder J, Su Y, Liu F, Li B, Zhou Y, Ni B (2003) Divergent roles of GSK3 and CDK5 in APP processing. Biochem Biophys Res Commun 312:922–929PubMedCrossRefGoogle Scholar
  56. Schroeter H, Boyd C, Spencer JP, Williams RJ, Cadenas E, Rice-Evans C (2002) MAPK signaling in neurodegeneration: influences of flavonoids and of nitric oxide. Neurobiol Aging 23:861–880PubMedCrossRefGoogle Scholar
  57. Selkoe DJ (2002) Alzheimer’s disease is a synaptic failure. Science 298:789–791PubMedCrossRefGoogle Scholar
  58. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I et al (2008) Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 14:837–842PubMedCrossRefPubMedCentralGoogle Scholar
  59. Sottocasa GL, Kuylenstierna B, Ernster L, Bergstrand A (1967) An electron-transport system associated with the outer membrane of liver mitochondria. A biochemical and morphological study. J Cell Biol 32:415–438PubMedCrossRefPubMedCentralGoogle Scholar
  60. Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL et al (2005) Axonopathy and transport deficits early in the pathogenesis of Alzheimer’s disease. Science 307:1282–1288PubMedCrossRefGoogle Scholar
  61. Su Y, Ryder J, Li B, Wu X, Fox N, Solenberg P et al (2004) Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry 43:6899–6908PubMedCrossRefGoogle Scholar
  62. Sun X, Sato S, Murayama O, Murayama M, Park JM, Yamaguchi H et al (2002) Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci Lett 321:61–64PubMedCrossRefGoogle Scholar
  63. Takamura A, Okamoto Y, Kawarabayashi T, Yokoseki T, Shibata M, Mouri A et al (2011) Extracellular and intraneuronal HMW-AbetaOs represent a molecular basis of memory loss in Alzheimer’s disease model mouse. Mol Neurodegener 6:20PubMedCrossRefPubMedCentralGoogle Scholar
  64. Takashima A, Noguchi K, Sato K, Hoshino T, Imahori K (1993) Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc Natl Acad Sci U S A 90:7789–7793PubMedCrossRefPubMedCentralGoogle Scholar
  65. Takashima A, Murayama M, Murayama O, Kohno T, Honda T, Yasutake K et al (1998) Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. Proc Natl Acad Sci U S A 95:9637–9641PubMedCrossRefPubMedCentralGoogle Scholar
  66. Tedeschi A, D’Errico G, Lauro MR, Sansone F, Di Marino S, D’Ursi AM et al (2010) Effect of flavonoids on the Abeta(25-35)-phospholipid bilayers interaction. Eur J Med Chem 45:3998–4003PubMedCrossRefGoogle Scholar
  67. Thotala DK, Geng L, Dickey AK, Hallahan DE, Yazlovitskaya EM (2010) A new class of molecular targeted radioprotectors: GSK-3beta inhibitors. Int J Radiat Oncol Biol Phys 76:557–565PubMedCrossRefPubMedCentralGoogle Scholar
  68. Tirkey N, Pilkhwal S, Kuhad A, Chopra K (2005) Hesperidin, a citrus bioflavonoid, decreases the oxidative stress produced by carbon tetrachloride in rat liver and kidney. BMC Pharmacol 5:2PubMedCrossRefPubMedCentralGoogle Scholar
  69. Trivedi PP, Tripathi DN, Jena GB (2011) Hesperetin protects testicular toxicity of doxorubicin in rat: role of NFkappaB, p38 and caspase-3. Food Chem Toxicol 49:838–847PubMedCrossRefGoogle Scholar
  70. Urbanc B, Cruz L, Le R, Sanders J, Ashe KH, Duff K et al (2002) Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer’s disease. Proc Natl Acad Sci U S A 99:13990–13995PubMedCrossRefPubMedCentralGoogle Scholar
  71. Valerio A, Bertolotti P, Delbarba A, Perego C, Dossena M, Ragni M et al (2011) Glycogen synthase kinase-3 inhibition reduces ischemic cerebral damage, restores impaired mitochondrial biogenesis and prevents ROS production. J Neurochem 116:1148–1159PubMedCrossRefGoogle Scholar
  72. Viswanatha GL, Shylaja H, Sandeep Rao KS, Santhosh Kumar VR, Jagadeesh M (2012) Hesperidin ameliorates immobilization-stress-induced behavioral and biochemical alterations and mitochondrial dysfunction in mice by modulating nitrergic pathway. ISRN Pharmacol 2012:479570PubMedCrossRefPubMedCentralGoogle Scholar
  73. Wang D, Gao K, Li X, Shen X, Zhang X, Ma C et al (2012) Long-term naringin consumption reverses a glucose uptake defect and improves cognitive deficits in a mouse model of Alzheimer’s disease. Pharmacol Biochem Behav 102:13–20PubMedCrossRefGoogle Scholar
  74. Wang DM, Li SQ, Zhu XY, Wang Y, Wu WL, Zhang XJ (2013a) Protective effects of hesperidin against amyloid-beta (Abeta) induced neurotoxicity through the voltage dependent anion channel 1 (VDAC1)-mediated mitochondrial apoptotic pathway in PC12 cells. Neurochem Res 38:1034–1044PubMedCrossRefGoogle Scholar
  75. Wang DM, Yang YJ, Zhang L, Zhang X, Guan FF, Zhang LF (2013b) Naringin enhances CaMKII activity and improves long-term memory in a mouse model of Alzheimer’s disease. Int J Mol Sci 14:5576–5586PubMedCrossRefPubMedCentralGoogle Scholar
  76. Wasowski C, Loscalzo LM, Higgs J, Marder M (2012) Chronic intraperitoneal and oral treatments with hesperidin induce central nervous system effects in mice. Phytother Res 26:308–312PubMedCrossRefGoogle Scholar
  77. Wilmsen PK, Spada DS, Salvador M (2005) Antioxidant activity of the flavonoid hesperidin in chemical and biological systems. J Agric Food Chem 53:4757–4761PubMedCrossRefGoogle Scholar
  78. Yeste-Velasco M, Folch J, Jimenez A, Rimbau V, Pallas M, Camins A (2008) GSK-3 beta inhibition and prevention of mitochondrial apoptosis inducing factor release are not involved in the antioxidant properties of SB-415286. Eur J Pharmacol 588:239–243PubMedCrossRefGoogle Scholar
  79. Zeevalk GD, Bernard LP, Song C, Gluck M, Ehrhart J (2005) Mitochondrial inhibition and oxidative stress: reciprocating players in neurodegeneration. Antioxid Redox Signal 7:1117–1139PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Dongmei Wang
    • 1
    Email author
  • Ling Liu
    • 2
  • Xiaoying Zhu
    • 1
  • Wenlan Wu
    • 1
  • Yong Wang
    • 1
  1. 1.Department of Pathogen Biology, Medical CollegeHenan University of Science and TechnologyLuoyangPeople’s Republic of China
  2. 2.Department of Pharmacy, Medical CollegeHenan University of Science and TechnologyLuoyangPeople’s Republic of China

Personalised recommendations